The impact of gender in cardiovascular medicine: Lessons from the gender/sex-issue in heart failure

Monaldi Arch Chest Dis. 2018 Oct 11;88(3):988. doi: 10.4081/monaldi.2018.988.

Abstract

Heart Failure (HF) is a major healthcare issue, given its high prevalence and incidence, the rate of comorbidities, the related high health-care costs and its poor outcome. In the last years mounting evidence revealed several differences between men and women affected by this clinical condition. Apart from the well-known difference in phenotype (HF with reduced ejection fraction (HFrEF) occurs more commonly in men, and HF with preserved ejection fraction (HFpEF) is more frequent in women) other relevant sex-related issues dwell upon epidemiology, presentation, risk stratification and management. These differences shed new lights on the possibility to consider HF as a prototype of the impact of gender/sex issue in cardiovascular medicine. A call for action and future strategies might help in the achievement of a cleaver patient-care.

Keywords: Heart Failure; gender.; sex.

Publication types

  • Review

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Age Distribution
  • Angiotensin Receptor Antagonists / therapeutic use
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Biomedical Research
  • Cardiac Resynchronization Therapy
  • Cardiology
  • Cardiovascular Diseases
  • Comorbidity
  • Defibrillators, Implantable
  • Female
  • Heart Failure / epidemiology*
  • Heart Failure / physiopathology
  • Heart Failure / therapy
  • Humans
  • Male
  • Precision Medicine
  • Sex Distribution
  • Sex Factors
  • Stroke Volume
  • Treatment Outcome
  • Ventricular Remodeling*

Substances

  • Adrenergic beta-Antagonists
  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors